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Abstract
Background: Large number of patients with colorectal liver metastasis show recurrent disease after curative surgical 
resection. Identification of these high-risk patients may guide therapeutic strategies. The aim of this study was to 
evaluate whether the presence of disseminated tumor cells in bone marrow from patients undergoing surgical 
resection of colorectal liver metastases can predict clinical outcome.
Methods: Sixty patients with colorectal liver metastases were planned for a curative resection between 2001 and 2007. 
All patients underwent bone marrow aspiration before surgery. Detection of tumor cells was performed using 
immunocytochemical staining for cytokeratin (CK-ICC) combined with automated microscopy or indirectly using 
reverse transcription-polymerase chain reaction (RT-PCR).
Results: Disseminated tumor cells were found in 15 of the 46 patients (33%) using CK-ICC and in 9 of 44 of the patients 
(20%) using RT-PCR. Patients with negative results for RT-PCR had a significant better disease-free survival after 
resection of their liver metastases (p = 0.02). This group also showed significant better overall survival (p = 0.002). CK-
ICC did not predict a worse clinical outcome.
Conclusions: The presence of disseminated tumor cells in bone marrow detected using RT-PCR did predict a worse 
clinical outcome. The presence of cells detected with CK-ICC did not correlate with poor prognosis.
Background
Over the past decades surgical resection has evolved as
the first choice of treatment for colorectal liver metasta-
ses because it is a relatively safe and potentially curative
procedure [1,2]. The reported 3-year survival of patients
after surgical resection of colorectal liver metastasis
ranges from 57% to 73% [3,4]. However, even after cura-
tive surgical resection, a high percentage of patients show
recurrent disease, either in the liver or extra hepatic,
within a relatively short period of time after surgical
treatment [5] caused by minimal residual disease (MRD)
[6]. These high-risk patients might benefit from addi-
tional systemic treatment [7]. Currently available prog-
nostic factors are insufficient to select patients at risk for
tumor progression [8]. Therefore the need for additional
methods for the selection of high-risk patients is evident.
On a clinical level, the Memorial Sloan-Kettering Can-
cer Center Clinical Risk Score (MSKCC-CRS) is a fre-
quently used tool to predict the risk for recurrence and
tumor progression [4]. On a cellular level, disseminated
tumor cells (DTCs) might also give this prognostic infor-
mation. DTCs can be detected in blood and bone marrow
of patients with various epithelial malignancies either
directly, using immunocytochemical staining combined
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with automated microscopy (CK-ICC), or indirectly
using reverse transcription-polymerase chain reaction
(RT-PCR) [6,9,10]. Automated microscopy is proven to
be an accurate method for pathological evaluation of
tumor cells in blood and bone marrow [11].
Currently, most data on the prognostic value of DTCs
are available for breast cancer. Recent meta-analysis [12]
showed that the presence of DTCs in bone marrow was
predictive for the development of distant metastases in
breast cancer. Tumor cell persistence in bone marrow
also showed to be an independent prognostic factor for
subsequent breast cancer survival [13].
However, in colorectal cancer the results are more con-
troversial. Different groups describe a positive associa-
t io n betw ee n D T C s in bo ne  m arr ow a nd a n incr eased
recurrence rate or reduced survival while other found no
association between DTCs and prognostic factors [6].
Therefore, the clinical meaning of DTC detection in col-
orectal cancer is still open for debate both for CK-ICC
and RT-PCR [14-19].
The aim of this prospective study is to evaluate whether
the presence of disseminated tumor cells in bone marrow
from patients undergoing surgical resection of colorectal
liver metastases is associated with worse overall survival
and shorter disease free survival.
Methods
Patients
Between October 2001 and November 2007, a total of
180 consecutive patients with colorectal liver metastases
were scheduled for surgical therapy. Only the patients
planned for curative resection were included in this
study. Other types of surgery or diagnoses were excluded:
surgery combined with radio frequency ablation (RFA) (n
= 25), RFA alone (n = 23), isolated liver perfusion (n =
64), liver perfusion prior to surgery (n = 2), benign dis-
ease (n = 2), other malignancy (n = 4). Overall, 60 patients
planned for resection of the liver metastases were
included for analysis. Twenty four of them were diag-
nosed in 2001-2004 and 36 were included in 2005-2007.
Approval from all the local Ethical Committees for this
study was granted and informed written consent was
obtained from all patients. All patients underwent a pre-
operative abdominal computed tomography (CT) to con-
firm metastatic disease confined to the liver. Eligibility
and exclusion criteria for the scheduled treatment and
criteria for disease progression within the liver according
to the WHO guidelines have been previously published
[1,20-23]. During follow-up, CT-scans of the liver were
made at 4, 8 and 12 months after surgery and then after
every 12 months until 3 years after surgery. The patients
who did not undergo any intervention or showed disease
progression which could not be surgically treated, were
referred to a medical oncologist for further treatment. All
patients underwent bone marrow aspiration under gen-
eral anesthesia just prior to surgery and all patients were
followed up until June 2008.
Bone marrow aspiration
5-10 ml of bone marrow was aspirated from both sides of
the anterior iliac crest of all included patients. Before
inserting the needle in the anterior iliac crest, an incision
was made into the overlying skin to prevent contamina-
tion with skin epithelial cells. Mononuclear cells were iso-
lated from bone marrow by ficoll gradient centrifugation
and aliquoted to isolate RNA to use for the RT-PCR or to
make cytospin-slides to stain with ICC.
Immunocytochemistry and automated microscopy (CK-ICC)
The cytospin slides were stained with primary antibodies
A45-B/B3, directed against cytokeratins 8, 18 and 19 or
with isotype control antibodies directed against an irrele-
vant antigen, MOPC21, as a negative control staining. A
detailed protocol has been published before by Pantel et
al [24]. This staining resulted in a red precipitate in the
cytoplasm of cytokeratin 8, 18 and 19-positive cells. The
slides were counterstained with hematoxylin to visualize
nuclear morphology. The stained slides were analysed
using the ARIOL SL-50 automated microscope®. One
slide stained for cytokeratin and one negative control
slide were analyzed per patient. The features of this sys-
tem have been previously published [25].
Combining ICC with automated microscopy, cytokera-
tin-positive cells were confirmed by a independent
pathologist and categorized based on morphological cri-
teria according to the guidelines of the European
ISHAGE Working Group for Standardization of Tumour
Cell Detection [26]. Candidate tumor cells and apoptotic
cells were cells that did not meet all criteria for a positive
cell but could not be unambiguously defined as normal. A
patient was considered positive if at least one tumor cell,
candidate tumor cell or apoptotic cell was found, all veri-
fied by an independent pathologist.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from the mononuclear cells by
T rizol reagent. Random primed cDNA was synthesized
from 1 μg of total RNA using the 1st strand cDNA synthe-
sis kit for RT-PCR (AMV). cDNA samples were five times
diluted to 100 μl to diminish pipetting variation. Primers
and probes for the marker CK20 were selected with
Primer Express®v1.5 software. The low-copy housekeep-
ing gene porphobilinogen deaminase was used as an
internal control. For each patient two RNA samples
resulting in cDNA samples were processed. Five micro-
liters of cDNA were used per amplification. For all PCRs
the same PCR conditions were used. Per reaction 300 nM
of each primer was used.Vogelaar et al. BMC Cancer 2010, 10:153
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PCR samples were considered positive if the threshold
cycle was less than 55. The threshold cycle reflects the
PCR cycle number at which the fluorescence generated
within a reaction crosses the threshold (background
noise). The threshold cycle is inversely proportional to
the copy number of the target template i.e. the higher the
template concentration, the lower the threshold cycle
measured. Bone marrow from a patient was considered
positive if at least one of the PCR samples was positive
after duplo analysis.
Statistical analysis
Frequencies were described as mean (SD), or median
(range) in case of a non-normal distribution. The mortal-
ity of the patients with positive RT-PCR was compared
with the subjects with negative RT-PCR using Cox
regression adjusted for sex and age. The same analysis
was done for CK-ICC. Hazard ratio's (HR) were calcu-
lated by Cox regression analysis for disease-related sur-
vival and disease-free survival. Disease-related survival
was considered from the day of liver metastases-surgery
to the day of death due to disease or censored at most
recent follow-up visit. Patients who did not undergo
resection of the liver metastases, who showed extra-
hepatic disease at the time of surgery or who died after
the operation due to complications or none disease-
related causes were excluded from disease-related sur-
vival analyses. Disease-free survival was considered from
the day of surgery to the day of recurrence or censored at
most recent follow-up. The association between mortal-
ity ans ICC or RT-PCR was visually depicted with a
Kaplan-Meier survival curve. All analyses were per-
formed with SPSS for Windows (version 16.0, SPSS Inc,
Chicago, Ill). P-values of less than 0.05 were considered
statistically significant.
Results
The study population comprised of 42 males and 18
females. No complications of bone marrow aspiration
were reported. Overall, 27% of the patients (16/60) did
not undergo the planned surgical treatment because of
the presence of extra-hepatic disease (n = 9), the high
number of metastases (n = 5) or the location of the
metastasis to the portal vein (n = 2). The median (range)
follow-up time from the date of diagnosis of the primary
tumor was 40.1 (7.6-96.3) months. 21 patients (35%) died
during follow-up: 17 patients due to disease progression,
one patient because of complications during surgery and
3 patients because of other none disease-related causes.
Median (SE) disease free survival of all the patients was
12.1 (1.9) months and the median (SE) overall survival
was 23.5 (1.8) months. One year survival was 93% and 3-
year survival 72%.
RT-PCR
Bone marrow samples of 16 patients could not be analy-
sed with RT-PCR because of the low amount of harvested
mononuclear cells. RT-PCR positivity was found in 9 of
44 of the patients (20%). A positive RT-PCR test was seen
in 6 of 32 patients (19%) who underwent a surgical resec-
tion compared to 3 of 12 inoperable patients (25%). Char-
acteristics of the patients analyzed with RT-PCR and CK-
ICC are shown in Table 1.
CK-ICC
Due to a low number of harvested mononuclear cells,
bone marrow samples of 14 colorectal liver metastases
patients could not be analysed using ICC combined with
automated microscopy to identify disseminated tumor
cells. 15 of the 46 patients (33%) had a positive ICC test.
IC C  bo n e  m a rr o w  a n a l y s i s  r e s u l t ed  i n  t h e  p r e se n c e  o f
tumour cells in 13 of 37 patients (35%) who underwent a
curative resection and 2 of 9 patients (22%) who finally
underwent no surgical resection (only abdominal explo-
ration).
MSKCC-CRS
Primary tumor stage showed no correlation with the
detection of tumor cells in bone marrow. High risk score-
patients (3-5) according to the MSKCC-CRS showed dis-
seminated tumor cells (RT-PCR) in 31% compared to 15%
in the low risk group (0-2). CK-ICC positivity was found
in 21% of the high-risk score-patients compared to 38% of
the low risk score-patients.
Pre-operative chemotherapy
Bone marrow of patients receiving neo-adjuvant chemo-
therapy was CK-ICC positive in 19% versus 40% in
patients not receiving chemotherapy. RT-PCR positivity
was found in 33% of the patients with chemotherapy
compared to 14% of the patients without chemotherapy.
Combining the two techniques (CK-ICC and/or RT-PCR
positive), 57% of bone marrow was negative in patients
who received chemotherapy and 54% in patients without
pre-operative chemotherapy. Survival in the group
receiving pre-operative chemotherapy was better than in
the non chemotherapy group (p = 0.02). This was also
seen when patients who did not undergo resection were
excluded from this analysis (p = 0.03).
Survival
Patients with RT-PCR negative bone marrow had a signif-
icant better overall survival (Figure 1); HR 6.40, 95% CI
1.93-21.16, p = 0.002. This group also showed significant
better disease-free survival after resection of their liver
metastases (Figure 2); HR 4.11, 95% CI.1.33-12.58, p =
0.02.
CK-ICC positive bone marrow showed no significant
difference in overall survival after resection (p = 0.24)Vogelaar et al. BMC Cancer 2010, 10:153
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neither a significant difference in disease-free survival (p
= 0.86).
Combined RT-PCR and/or ICC positive analysis did
not show any overall survival difference (p = 0.68) neither
a difference in disease-free survival (p = 0.60). The low
risk group according to the MSKCC-CRS (0-2) had a bet-
ter overall survival (HR 3.32, 95%CI 1.14-9.67, p = 0.03)
compared to the high MSKCC-CRS (3-5) patients. All HR
were adjusted for age and sex.
When adjusted for MSKCC-CRS score, also a signifi-
cant better overall survival was found in RT-PCR negative
patients; HR 5.42, 95% CI.1.53-19.18, p = 0.009.
Discussion
In our study disseminated tumor cells found in bone mar-
row by RT-PCR have prognostic value in patients sched-
uled for surgical resection of colorectal liver metastases.
Patients with positive bone marrow by RT-PCR had an
increased risk of cancer related mortality. Also adjusted
for the MSKCC risk score, RT-PCR positivity showed a
significant worse overall survival which reflects its addi-
tional medical value. In contrast, ICC did not predict out-
come in these patients.
In our study the patients with positive RT-PCR bone
marrow showed worse overall and disease-free survival
Table 1: Characteristics of the patients analyzed with RT-PCR and CK-ICC.
RT-PCR CK-ICC
positive
N = 9
negative
N = 35
positive
N = 15
negative
N = 31
Male 5 (56) 26 (74) 12 (80) 20 (65)
Age (years), mean (se) 63.4 (3.7) 60.9 (1.3) 62.9 (2.3) 60.2 (1.6)
TNM stage of primary tumor
1 1 (11) 3 (9) 2 (13) 1 (3)
2 1 (11) 6 (17) 2 (13) 4 (13)
3 3 (33) 9 (26) 5 (33) 8 (26)
4 4 (45) 17 (49) 6 (40) 18 (58)
Time span between PT and LM (months)
< 12 6 (67) 20 (57) 8 (53) 23 (74)
> 12 3 (33) 15 (43) 7 (47) 8 (26)
Preoperative systemic chemotherapy
No 4 (44) 25 (71) 12 (80) 18 (58)
Yes 5 (56) 10 (29) 3 (20) 13 (42)
Serum CEA level
< 200 ug/l 5 (55) 30 (86) 13 (87) 25 (81)
> 200 ug/l 1 (11) 3 (9) 1 (7) 2 (7)
not assessed 3 (33) 2 (5) 1 (7) 4 (14)
No. of liver metastases
1 3 (33) 14 (40) 5 (33) 12 (39)
> 1 6 (67) 21 (60) 10 (67) 19 (61)
Diameter of liver metastases (cm)
< 5 7 (77) 28 (80) 12 (80) 26 (84)
> 5 2 (33) 7 (20) 3 (20) 5 (16)
MSKCC clinical risk score
0-2 (low) 4 (44) 24 (69) 12 (80) 20 (65)
≥ 3 (high) 5 (56) 11 (31) 3 (20) 11 (35)
Death 6 (67) 10 (29) 5 (33) 14 (45)
Data presented in number (%), unless otherwise stated.
*Abbreviations; PT, primary tumor; LM, liver metastases; CEA, carcino embryonic antigen; MSKCC, memorial sloan-kettering cancer center.Vogelaar et al. BMC Cancer 2010, 10:153
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after liver metastasis surgery. Similar results were found
by Koch et al [15]. This study investigated bone marrow
samples from 25 patients with colorectal liver metastases
who underwent surgical resection and showed a positive
RT-PCR test to be an independent prognostic factor for
recurrence-free survival. The percentage RT-PCR posi-
tive bone marrow of the patients in our study (20.5%), is
comparable with other studies, showing 16-27% RT-PCR
positivity [15,18,19].
In contrast to RT-PCR, a positive ICC did not predict
worse overall- and disease-free survival. Studies from
Bjornland et al and Schoppmeyer et al had the same con-
clusion [14,17]. In contrast, DTCs detected with the CK-
ICC in breast cancer patients are found to be of major
prognostic significance [27]. It might be argued that the
bone marrow in breast cancer patients not just reflects
the metastatic load but is also a preferred site for metas-
tases outgrowth. This may relate to the possibility that
the bone marrow compartment offers a more fertile
microenvironment for breast cancer cells than for col-
orectal cancer cells [28].
ICC positivity in bone marrow in our study is 32.6%.
Differences in percentages of ICC positivity in colorectal
cancer are reported in literature; Schoppmeyer et al found
55% CK positive cells in bone marrow [17], Cohen et al
found 9.5-34% ICC positivity [29] and Bjornland et al
found 8% ICC positivity [14].
The two methods used in our study to detect DTCs in
liver metastatic colorectal cancer showed different
results. A possible explanation is the hypothesis that only
a small subset of tumor cells has the capacity to prolifer-
ate extensively and to outgrow to new tumors as increas-
ing evidence supports [30,31]. Alternative detection
methods, therefore may find disseminated cells that differ
in their tumor initiating capacities. Another explanation
may be that ICC detects only intact cells, while RT-PCR
can also detect fragments of cells that are degraded in the
circulation. Intact cells then may be considered biologi-
cally irrelevant (thus left alone by the immune system).
Cells that would have been attacked by the immune sys-
tem but escaped in distant organs may find a niche there
to evolve into clinically manifest disease. Although highly
speculative this same phenomenon has been described in
minimal residual disease detection in lymph nodes [8],
where RT-PCR is also more prognostic then ICC.
Figure 1 Graphical representation of the relationship between reverse transcription-polymerase chain reaction (RT-PCR) status and over-
all survival in subjects after colorectal liver metastases surgery.Vogelaar et al. BMC Cancer 2010, 10:153
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Earlier report from Vlems et al showed no positive
bone marrow in 12 of the 20 patients who underwent
chemotherapy and the authors therefore suggest chemo-
therapy prevents shedding or accelerates clearance of dis-
seminated tumor cells [18]. However, we found no
influence of preoperative chemotherapy on bone marrow
positivity.
Possible limitations and strength
The clinical relevance of the molecular detection of DTCs
is possibly restricted by tumor cell heterogenity and dif-
fering sensitivity and specificity of each specific detection
method. This may explain inconclusive findings from
previous disseminated tumor cell studies. Despite the
small number of patients, to the best of our knowledge
our study is the largest study comparing both techniques,
CK-ICC and RT-PCR, in patients with metastatic col-
orectal cancer.
Conclusion
The presence of disseminated tumor cells in bone mar-
row of patients with colorectal cancer detected with RT-
PCR does predict a worse clinical outcome in our study.
Positive ICC did not find to have this predictive value. In
the future, a more detailed and also functional analysis of
the cells found in bone marrow of colorectal cancer
patients may help in therapy selection and may give bet-
ter prognostic information and as such contribute to
patient management.
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